Peter J. Dandliker
Director
Merck
Professional Background: Dr. Dandliker leads the Merck ALIS affinity screening group, located in Boston. In 20 years of pharmaceutical discovery research, Peter has held a range of leadership roles at the chemistry / biology interface, establishing teams dedicated to hit-to-lead medicinal chemistry and biology, high-throughput ADME, and founding a research lab on behalf of a western pharma company in Shanghai. He enjoys purposeful technical innovation in the areas of target & lead discovery, pharmacological characterization, and chemical optimization, and applying those new capabilities to discovery programs. He holds a Ph.D. in organic chemistry from UCLA and performed his postdoctoral work at the California Institute of Technology.
Presentation(s):
-
ALIS Affinity Selection in Pharmaceutical Discovery
Wednesday, February 7
9:30 AM – 10:00 AM